Qinggao Zhang

Qinggao Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JXJia-Chen Xue
Jia-Chen Xue
SYShuo Yuan
Shuo Yuan
HMHuan Meng
Huan Meng
XHXiao-Ting Hou
Xiao-Ting Hou
JLJiao Li
Jiao Li
QZQinggao Zhang
Qinggao Zhang
Ulcerative colitis (UC) is a chronic inflammatory disease of the intestine that presents clinically with abdominal pain, mucopurulent stools, and posterior urgency. The lesions of UC are mainly concentrated in the rectal and colonic mucosa and submucosa. For patients with mild to moderate UC, the best pharmacological treatment includes glucocorticoids, immunosuppressants, antibiotics, and biologics, but the long-term application can have serious toxic side effects. Currently, nearly 40% of UC patients are treated with herbal natural products in combination with traditional medications to reduce the incidence of toxic side effects. Flavonoid herbal natural products are the most widely distributed polyphenols in plants and fruits, which have certain antioxidant and anti-inflammatory activities. Flavonoid herbal natural products have achieved remarkable efficacy in the treatment of UC. The pharmacological mechanisms are related to anti-inflammation, promotion of mucosal healing, maintenance of intestinal immune homeostasis, and regulation of intestinal flora. In this paper, we summarize the flavonoid components of anti-ulcerative colitis and their mechanisms reported in the past 10 years, to provide a basis for rational clinical use and the development of new anti-ulcerative colitis drugs.

10 October 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MJMeihua Jin
Meihua Jin
CWChun Wang
Chun Wang
YXYifeng Xu
Yifeng Xu
ZZZijing Zhang
Zijing Zhang
XWXueyan Wu
Xueyan Wu
DHDonghe Han
Donghe Han
Salidroside (SAL) is a phenylpropanoid glycoside monomer extracted from Rhodiola at high altitudes. It has been proven to have protective effects on myocardial injury, liver cancer, renal fibrosis, and other organ diseases, as well as play neuroprotective roles in central nervous system (CNS) diseases. Specifically, SAL can inhibit a series of pathological reactions in CNS diseases and improve neurological dysfunction. This review elucidated the pharmacological effects of SAL on inflammation, oxidative stress, apoptosis, autophagy, and neuronal regeneration. Furthermore, how SAL affects various signaling pathways to regulate pathological processes in CNS diseases is also assessed. However, the relationship between various pathways and the mechanisms in different pathological stages remains unclear. Additionally, the appropriate dosage and side effects of SAL on the clinical outcomes of CNS diseases have not been fully determined due to the limited number of clinical studies on SAL. Therefore, the regulatory mechanisms and clinical applications of SAL still need to be further demonstrated. This review tracked and summarized studies from the past eight years reported in databases, including PubMed, ScienceDirect, and Google Scholar, filtered using the keywords "salidroside" and/or paired with "diseases" and "CNS diseases".

7 July 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SYShuo Yuan
Shuo Yuan
YLYou Li
You Li
JLJiao Li
Jiao Li
JXJia-Chen Xue
Jia-Chen Xue
QWQi Wang
Qi Wang
QZQinggao Zhang
Qinggao Zhang
Inflammatory bowel disease (IBD) is a rare, recurrent, and intractable inflammation obstruction of the stomach tract, usually accompanied by inflammation of cell proliferation and inflammation of the colon and carries a particular cause of inflammation. The clinical use of drugs in western countries affects IBD treatment, but various adverse effects and high prices limit their application. For these reasons, Traditional Chinese Medicine (TCM) is more advantageous in treating IBD. This paper reviews the mechanism and research status of TCM and natural products in IBD treatment by analyzing the relevant literature to provide a scientific and theoretical basis for IBD treatment.

Verified
Journal Article
Open access
PDF file
HZhuamin zhang
huamin zhang
SYShuo Yuan
Shuo Yuan
HMHuan Meng
Huan Meng
XHXiao-Ting Hou
Xiao-Ting Hou
JLJiao Li
Jiao Li
QZQinggao Zhang
Qinggao Zhang
Inflammatory bowel disease (IBD) is a chronic, relapsing disease that severely affects patients’ quality of life. The exact cause of IBD is uncertain, but current studies suggest that abnormal activation of the immune system, genetic susceptibility, and altered intestinal flora due to mucosal barrier defects may play an essential role in the pathogenesis of IBD. Unfortunately, IBD is currently difficult to be wholly cured. Thus, more treatment options are needed for different patients. Stem cell therapy, mainly including hematopoietic stem cell therapy and mesenchymal stem cell therapy, has shown the potential to improve the clinical disease activity of patients when conventional treatments are not effective. Stem cell therapy, an emerging therapy for IBD, can alleviate mucosal inflammation through mechanisms such as immunomodulation and colonization repair. Clinical studies have confirmed the effectiveness of stem cell transplantation in refractory IBD and the ability to maintain long-term remission in some patients. However, stem cell therapy is still in the research stage, and its safety and long-term efficacy remain to be further evaluated. This article reviews the upcoming stem cell transplantation methods for clinical application and the results of ongoing clinical trials to provide ideas for the clinical use of stem cell transplantation as a potential treatment for IBD.

23 October 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
SCShan Cui
Shan Cui
CWChenhui Wang
Chenhui Wang
WBWeizhi Bai
Weizhi Bai
JLJiao Li
Jiao Li
YPYue Pan
Yue Pan
YCYongwen Chen
Yongwen Chen
IGB3/CD1d1 determines the severity of DSS-colitis through inhibiting Nlrp3 , Il1b , and Il18 transcription in macrophages.

2 October 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JXJiachen Xue
Jiachen Xue
SYShuo Yuan
Shuo Yuan
XHXiao-Ting Hou
Xiao-Ting Hou
HMHuan Meng
Huan Meng
BLBao-Hong Liu
Bao-Hong Liu
QZQinggao Zhang
Qinggao Zhang
Ulcerative colitis (UC) is a clinically common, progressive, devastating, chronic inflammatory disease of the intestine that is recurrent and difficult to treat. Nod-like receptor protein 3 (NLRP3) is a protein complex composed of multiple proteins whose formation activates cysteine aspartate protease-1 (caspase-1) to induce the maturation and secretion of inflammatory mediators such as interleukin (IL)-1β and IL-18, promoting the development of inflammatory responses. Recent studies have shown that NLRP3 is associated with UC susceptibility, and that it maintains a stable intestinal environment by responding to a wide range of pathogenic microorganisms. The mainstay of treatment for UC is to control inflammation and relieve symptoms. Despite a certain curative effect, there are problems such as easy recurrence after drug withdrawal and many side effects associated with long-term medication. NLRP3 serves as a core link in the inflammatory response. If the relationship between NLRP3 and gut microbes and inflammation-associated factors can be analyzed concerning its related inflammatory signaling pathways, its expression status as well as specific mechanism in the course of IBD can be elucidated and further considered for clinical diagnosis and treatment of IBD, it is expected that the development of lead compounds targeting the NLRP3 inflammasome can be developed for the treatment of IBD. Research into the prevention and treatment of UC, which has become a hotbed of research in recent years, has shown that natural products are rich in therapeutic means, and multi-targets, with fewer adverse effects. Natural products have shown promise in treating UC in numerous basic and clinical trials over the past few years. This paper describes the regulatory role of the NLRP3 inflammasome in UC and the mechanism of recent natural products targeting NLRP3 against UC, which provides a reference for the clinical treatment of this disease.